LivaNova (NASDAQ:LIVN) Issues FY 2026 Earnings Guidance

LivaNova (NASDAQ:LIVN - Get Free Report) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 4.200-4.300 for the period, compared to the consensus estimate of 4.100. The company issued revenue guidance of $1.4 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. The Goldman Sachs Group reiterated a "neutral" rating and issued a $66.00 price target on shares of LivaNova in a report on Friday, January 9th. Piper Sandler reiterated an "overweight" rating and set a $85.00 price target on shares of LivaNova in a research report on Thursday, February 19th. Needham & Company LLC increased their price target on shares of LivaNova from $64.00 to $81.00 and gave the stock a "buy" rating in a research note on Wednesday, February 25th. Weiss Ratings restated a "sell (d+)" rating on shares of LivaNova in a report on Friday, March 27th. Finally, Stifel Nicolaus set a $80.00 price objective on LivaNova in a research report on Wednesday, February 25th. Seven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $74.78.

LivaNova Trading Down 2.5%

Shares of NASDAQ LIVN opened at $57.59 on Wednesday. LivaNova has a 1 year low of $35.00 and a 1 year high of $71.92. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.36 and a quick ratio of 1.16. The firm has a 50-day moving average of $64.01 and a 200 day moving average of $61.94. The stock has a market cap of $3.16 billion, a P/E ratio of -12.91 and a beta of 0.82.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.86 earnings per share for the quarter, topping analysts' consensus estimates of $0.80 by $0.06. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The business had revenue of $360.92 million for the quarter, compared to analysts' expectations of $354.31 million. During the same quarter in the prior year, the company earned $0.81 earnings per share. The business's revenue was up 12.2% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. As a group, sell-side analysts expect that LivaNova will post 3.66 EPS for the current fiscal year.

Institutional Investors Weigh In On LivaNova

Several hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC increased its holdings in shares of LivaNova by 22.4% during the third quarter. Millennium Management LLC now owns 2,969,814 shares of the company's stock valued at $155,559,000 after acquiring an additional 544,033 shares in the last quarter. Wellington Management Group LLP boosted its stake in LivaNova by 83.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company's stock worth $122,858,000 after purchasing an additional 1,067,349 shares in the last quarter. AQR Capital Management LLC boosted its stake in LivaNova by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company's stock worth $132,606,000 after purchasing an additional 496,165 shares in the last quarter. Dimensional Fund Advisors LP grew its position in LivaNova by 3.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,787,928 shares of the company's stock valued at $110,014,000 after purchasing an additional 66,755 shares during the last quarter. Finally, Invesco Ltd. grew its position in LivaNova by 4.5% during the 4th quarter. Invesco Ltd. now owns 1,091,086 shares of the company's stock valued at $67,135,000 after purchasing an additional 47,323 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company's primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.